정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2032 | Recruiting | Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection | Covid19 | Drug: Tocilizumab Drug: Heparin - Therapeutic dosage Drug: Heparin - Prophylactic dosage |
Phase 3 | University of Sao Paulo, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico | OTHER | 308 | All | 18 Years | Fundacao Sao Francisco Xavier, Ipatinga, Minas Gerais, Brazil UNIMED Varginha, Varginha, Minas Gerais, Brazil Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil |
2031 | Not yet recruiting | Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia | COVID-19 | Drug: Nafamostat Mesylate | Phase 3 | Gyeongsang National University Hospital | OTHER | 84 | All | 18 Years ~ 85 Years | |
2030 | Recruiting | Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19 | Covid19 | Drug: Vitamin C 500 MG Oral Tablet Drug: Tenofovir disoproxyl fumarate 300 MG Oral Tablet Drug: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet |
Not Applicable | Universidade Federal do Ceara, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Sao Jose Hospital for Infectious Diseases - HSJ, Central Laboratory of Public Health of Ceara - Lacen-CE | OTHER | 219 | All | 18 Years | Nucleo de Biomedicina - NUBIMED, Fortaleza, Ceara, Brazil |
2029 | Active, not recruiting | Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection | COVID-19 | Biological: Bactek-R | Phase 3 | Inmunotek S.L., BioClever 2005 S.L. | INDUSTRY | 100 | All | 18 Years ~ 70 Years | Hospital Metropolitano Santiago, Santiago De Los Caballeros, Dominican Republic |
2028 | Recruiting | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | COVID-19 | Biological: UC-MSCs Other: Placebo |
Phase 2 | Puren Hospital Affiliated to Wuhan University of Science and Technology, Shanghai University, Qingdao Co-orient Watson Biotechnology group co. LTD, Chinese Academy of Medical Sciences | OTHER | 30 | All | 18 Years ~ 75 Years | Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China |
2027 | Not yet recruiting | Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? | Covid19 | Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone Drug: The standard therapy |
Phase 4 | Kafrelsheikh University | OTHER | 1000 | All | 18 Years ~ 70 Years | |
2026 | Recruiting | Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 | SARS-CoV Infection | Drug: Placebo administration Diagnostic Test: Confirm SARS-CoV-2 infection Procedure: Physical Examination Procedure: Vital Signs Diagnostic Test: Hematology blood test Diagnostic Test: Biochemistry blood test Other: NEWS score Diagnostic Test: PK test Diagnostic Test: blood test for inflammatory markers Diagnostic Test: D-dimer test Other: VAS scale Diagnostic Test: Urine pregnancy test for women of childbearing potential Procedure: ECG Other: COVID-19-Impact on Quality of Life Questionnaire Drug: CimetrA-1 Drug: CimetrA-2 |
Phase 3 | MGC Pharmaceuticals d.o.o | INDUSTRY | 252 | All | 18 Years | Nazareth Hospital EMMS, Nazareth, North, Israel Rambam Medical Center, Haifa, Israel |